Skip to content
BillRazor
Generic J2405 · GI / Acid Suppression

ONDANSETRON HCL 4 MG/2 ML VIAL

Ondansetron HCL 4 MG/2 ML vial, a generic anti-nausea medication, has an acquisition cost of $0.20 while hospitals typically charge patients significantly more for the same dose.

By Kevin Nyk , Medical Billing Analyst · ·
Data from CMS files published FY 2024 CMS IPPS. Refreshed weekly.
About the analyst

Kevin Nyk analyzes hospital pricing data at BillRazor Research. He specializes in Medicare reimbursement patterns and chargemaster pricing across U.S. hospitals. Expertise: hospital pricing, Medicare rates, chargemaster analysis.

NADAC acquisition cost data
CMS drug pricing benchmarks
Updated 2026-04-03
Drug acquisition cost — ONDANSETRON HCL 4 MG/2 ML VIAL
NADAC cost$0.2020 per unit
Hospital charges for this drug vary — typically 3–8x the acquisition cost. No observed hospital charge data is available for this specific drug.
$0.20
NADAC acquisition cost
INJECTABLE
Dosage form
INJECTION
Route

Ondansetron HCL is an anti-nausea medication commonly administered in hospital settings for chemotherapy patients and post-operative care. This injectable formulation typically generates higher facility charges compared to oral tablets, with potential billing variations of several hundred dollars between inpatient and outpatient administration codes.

Check your bill amount
Enter the charge for ONDANSETRON HCL 4 MG/2 ML VIAL from your bill to compare against the NADAC acquisition cost.
$

No credit card required. Results in 60 seconds.

Research suggests 49–80% of hospital bills contain errors. Our system checks every line item against Medicare benchmarks.

Common billing errors — GI / Acid Suppression charges

Hospital billing for GI and acid suppression medications frequently shows charges above the benchmark, with markups ranging from 300-800% over the average $0.25 NADAC acquisition cost. Common billing issues include duplicate charges when patients receive both immediate-release and extended-release formulations of the same medication, such as omeprazole, without clear documentation of medical necessity. Generic substitution problems occur when hospitals bill for brand-name proton pump inhibitors like Nexium while dispensing generic esomeprazole, creating potential differences of $15-40 per dose. Patients should verify that IV formulations are appropriately billed only when oral administration is contraindicated, as IV pantoprazole can be charged at 10-15 times the cost of oral equivalents. Bundle billing errors also appear when acid suppressants administered as part of surgical protocols are separately itemized rather than included in procedure costs, particularly with histamine-2 receptor antagonists like famotidine.

Rates shown are from the 2026 Medicare Physician Fee Schedule and CMS IPPS. BillRazor compares your bill against these data sources. See how it works →

FAQ — GI / Acid Suppression billing

What is the average acquisition cost for GI/Acid Suppression drugs?
The average NADAC acquisition cost for GI/Acid Suppression drugs is $0.25. This benchmark represents the national average drug acquisition cost used for comparison in billing analysis.
How many drugs are included in the GI/Acid Suppression class for billing purposes?
There are 21 drugs classified within the GI/Acid Suppression therapeutic category. This classification helps standardize billing review and cost comparison processes across similar medications.
How should charges above the benchmark be documented for GI/Acid Suppression drugs?
Charges above the $0.25 benchmark should be documented with supporting acquisition cost evidence and justification. Proper documentation helps substantiate billing differences and supports audit compliance for these medications.
What billing considerations apply when reviewing GI/Acid Suppression drug costs?
Billing review should compare actual acquisition costs against the $0.25 NADAC benchmark to identify potential differences. The analysis covers all 21 drugs in this therapeutic class to ensure comprehensive cost evaluation and billing accuracy.

Related pricing data

Data source: National Average Drug Acquisition Cost (NADAC) survey, published by CMS. HCPCS drug pricing codes from Medicare Part B Drug Average Sales Price file.

What NADAC means: The average price pharmacies pay to acquire this drug from wholesalers. Hospital charges for the same drug are typically higher due to facility fees, compounding, and administration costs.

Limitations: NADAC reflects pharmacy acquisition cost, not patient out-of-pocket cost. Insurance copays, formulary tiers, and manufacturer rebates affect what patients actually pay.

Upload your bill — free instant analysis